Schwab Charles Investment Management Inc. cut its position in shares of Fluidigm Corporation (NASDAQ:FLDM) by 24.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,735 shares of the medical research company’s stock after selling 24,150 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.26% of Fluidigm Corporation worth $431,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Acadian Asset Management LLC raised its holdings in shares of Fluidigm Corporation by 46.0% in the first quarter. Acadian Asset Management LLC now owns 301,705 shares of the medical research company’s stock worth $1,716,000 after buying an additional 95,056 shares during the period. Russell Investments Group Ltd. increased its holdings in Fluidigm Corporation by 0.9% during the 1st quarter. Russell Investments Group Ltd. now owns 2,258,937 shares of the medical research company’s stock worth $12,849,000 after purchasing an additional 19,725 shares during the period. Wells Fargo & Company MN increased its holdings in Fluidigm Corporation by 15.0% during the 1st quarter. Wells Fargo & Company MN now owns 25,521 shares of the medical research company’s stock worth $146,000 after purchasing an additional 3,327 shares during the period. Bank of New York Mellon Corp increased its holdings in Fluidigm Corporation by 20.5% during the 1st quarter. Bank of New York Mellon Corp now owns 206,578 shares of the medical research company’s stock worth $1,175,000 after purchasing an additional 35,176 shares during the period. Finally, Levin Capital Strategies L.P. increased its holdings in Fluidigm Corporation by 0.6% during the 1st quarter. Levin Capital Strategies L.P. now owns 5,789,282 shares of the medical research company’s stock worth $32,941,000 after purchasing an additional 33,529 shares during the period. Institutional investors and hedge funds own 88.85% of the company’s stock.
A number of analysts have recently weighed in on FLDM shares. ValuEngine lowered Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Zacks Investment Research upgraded Fluidigm Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, June 1st.
WARNING: This piece was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://baseballnewssource.com/markets/fluidigm-corporation-fldm-holdings-trimmed-by-schwab-charles-investment-management-inc/1604233.html.
In related news, insider Levin Capital Strategies, L.P. bought 60,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was purchased at an average cost of $5.25 per share, for a total transaction of $315,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Stephen Christopher Linthwaite bought 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The shares were bought at an average price of $2.66 per share, with a total value of $119,700.00. Following the completion of the purchase, the chief executive officer now owns 106,977 shares in the company, valued at $284,558.82. The disclosure for this purchase can be found here. Insiders acquired 4,166,038 shares of company stock valued at $13,811,083 over the last three months. Insiders own 4.70% of the company’s stock.
Shares of Fluidigm Corporation (FLDM) opened at 5.15 on Friday. Fluidigm Corporation has a 12-month low of $2.52 and a 12-month high of $8.69. The firm’s market capitalization is $151.48 million. The company has a 50-day moving average price of $4.15 and a 200 day moving average price of $4.56.
Fluidigm Corporation (NASDAQ:FLDM) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.58) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.02. The firm had revenue of $23.90 million for the quarter, compared to the consensus estimate of $23.50 million. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 121.04%. The firm’s revenue was down 15.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.63) earnings per share. On average, equities analysts expect that Fluidigm Corporation will post ($2.13) earnings per share for the current year.
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with our FREE daily email newsletter.